MedPacto announced on Jan. 2 that it has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for the combination therapy of Vactosertib and Pembrolizumab (commercially known as Keytruda).This clinical trial targets patients with previo
Incheon Free Economic Zone (IFEZ) celebrates its 20th anniversary on Oct. 15, marking two decades of steering South Korea’s economic growth.Incheon Free Economic Zone (IFEZ), composed of Songdo, Cheongna, and Yeongjong International Cities, was designated as South Korea’s first free economic zone on
The author is an analyst for NH Investment & Securities. He can be reached at kyuha.lee@nhqv.com -- Ed.Phase III MARIPOSA meets primary endpointJanssen announced positive topline results from the pivotal phase III MARIPOSA study evaluating Rybrevant (amivantamab) in combination with lazertinib, a th
TiumBio Co., Ltd. (KRX: 321550. KQ), a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapeutics for patients with rare and incurable diseases, today announced that the Phase 1a results of TU2218 will be presented at the 2023 European Society of Medical
Nine merger and acquisition (M&A) deals worth more than US$1 billion were made in the global pharmaceutical and bio industries in the first half of this year.According to the Korea Biotechnology Industry Organization (KBIO) on July 2, the global pharmaceutical and bio industries recorded nine M&A de
Kim Jin-yong, chief of the Incheon Free Economic Zone Authority (IFEZA), emphasized on June 29 at the annual conference hosted by Urban Land Institute (ULI) Korea, “We will foster the Songdo Bio Cluster into a global bio hub, establishing it as a future growth engine for the Incheon Free Economic Zo
Samsung Electronics Chairman Lee Jae-yong met with global CEOs of big pharmaceutical companies and bio-venture startup incubation companies in the eastern United States, the world’s largest bio-cluster, to lay the groundwork for the success of Samsung’s biotech business.According to Samsung Electron
Germany's Merck Life Sciences will set up an Asia-Pacific production facility for biopharmaceutical raw materials and parts in Daejeon, Korea.Merck Life Sciences announced on May 3 that it has signed a memorandum of understanding (MOU) with the Ministry of Trade, Industry and Energy and Daejeon
Samsung Biologics plans to build a fifth plant in Songdo, Incheon, Korea by investing more than 1 trillion won (US$768 million). Previously, the company laid out a plan to build a second campus in October of last year and invest 7.5 trillion won (US$5.8 billion) in the construction of its fifth and
Vestas, the world’s largest wind turbine manufacturer, reported a US$300 million investment in South Korea at the World Economic Forum in Davos, Switzerland.An investment report signing ceremony was held at a hotel in Davos in the presence of Trade, Industry and Energy Minister Lee Chang-yang and Ve
The author is an analyst of KB Securities. He can be reached at kimtaehee@kbfg.com. -- Ed. Slightly lower target price to KRW350,000 on WACC increase We slightly lower our TP (KRW380,000→KRW350,000) on Hanmi Pharm. While we revise up our earnings estimates to reflect 3Q22 results, we raise RFR to 3.
The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and sehunjang@shinhan.com, respectively. – Ed. Positive clinical data for HER2 ADC presented at the World ADCAt the World ADC 2022 conference held on September 7 (local time), there was an announcement
The author is an analyst of KB Securities. He can be reached at kimtaehee@kbfg.com. -- Ed. Recommend BUY, target price of KRW380,000 We recommend BUY and TP of KRW380,000 on Hanmi Pharm. We highlight the 2Q22 earnings surprise, steady 2H22 growth forecasts for Korea/China, the release schedule of cl
COVID-19 vaccine and drug developers are in a dilemma. They are wishing to stop the development process in view of the difficulty and the fact that what they develop is unlikely to be profitable. However, they are hesitating to announce ahead of the others for potential criticism from the public.Acc
Germany's Merck is set to start production of chemical mechanical polishing (CMP) slurry in Korea.The company is conducting a quality test on CMP slurry with its Korean customers. The company is expected to begin delivery in the first half of 2022.CMP slurry is a material that is used to polish
The importance of mRNA-related technologies is continuing to increase for its potential to cure cancers, dementia, and other diseases. However, the use of mRNA in South Korea is still limited to COVID-19 vaccine development, and this is because of the lack of original technology.Merck announced in J
Hanmi Pharmaceutical announced on Jan. 20 that it will speed up the production of a generic version of Merck & Co.'s COVID-19 pill, molnupiravir (product name: Lagevrio), for supply to 105 low- and middle-income countries.Hanmi Pharmaceutical is one of the three Korean generic drug manufacturers
Global leaders in the semiconductor and display industries are increasing their R&D investments in South Korea and strengthening their partnerships with South Korean companies in the industries.German company Merck recently decided to invest 600 million euros in South Korea for four years to come. I
German life science giant Sartorius will invest US$300 million to build a biopharmaceutical raw material plant in Songdo International City of the Incheon Free Economic Zone (IFEZ).IFEZ Authority announced on Nov. 2 that the German company signed an MOU on facility investment in Songdo with the Kore
Minority shareholders of Celltrion are stepping up pressure on the company's management to come up with measures against the recent plunge in the stock price.Celltrion's minority shareholders have recently agreed to wage an all-out war against the company’s management and are campaigning to